Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells

British Journal of Haematology

Volumn 155, Issue 5, 2011, Pages 588-598

  Chauhan, Dharminder ^a   Bandi, Madhavi ^a   Singh, Ajita V ^a   Ray, Arghya ^a   Raje, Noopur ^a   Richardson, Paul ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Microenvironment; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CHECKPOINT KINASE 2; DEXAMETHASONE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SRT 1720; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELL LINE, TUMOR; DEXAMETHASONE; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MULTIPLE MYELOMA; PYRAZINES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81155148158     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08888.x     Document Type: Article

References (57)

1. Abdelmohsen, K., Pullmann, Jr, R., Lal, A., Kim, H.H., Galban, S., Yang, X., Blethrow, J.D., Walker, M., Shubert, J., Gillespie, D.A., Furneaux, H. & Gorospe, M. (2007) Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Molecular Cell, 25, 543-557.
2. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood, 109, 3489-3495.
3. Bergsagel, P.L. & Kuehl, W.M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23, 6333-6338.
4. Bergsagel, P.L., Chesi, M., Nardini, E., Brents, L.A., Kirby, S.L. & Kuehl, W.M. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 93, 13931-13936.
5. Bhalla, S., Balasubramanian, S., David, K., Sirisawad, M., Buggy, J., Mauro, L., Prachand, S., Miller, R., Gordon, L.I. & Evens, A.M. (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research, 15, 3354-3365.
6. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A.S., Shishodia, S. & Aggarwal, B.B. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109, 2293-2302.
7. Borra, M.T., O'Neill, F.J., Jackson, M.D., Marshall, B., Verdin, E., Foltz, K.R. & Denu, J.M. (2002) Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. The Journal of Biological Chemistry, 277, 12632-12641.
8. Bossy-Wetzel, E. & Green, D.R. (1999) Apoptosis: checkpoint at the mitochondrial frontier. Mutation Research, 434, 243-251.
9. Burger, R., Guenther, A., Bakker, F., Schmalzing, M., Bernand, S., Baum, W., Duerr, B., Hocke, G.M., Steininger, H., Gebhart, E. & Gramatzki, M. (2001) Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematology Journal, 2, 42-53.
10. Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y.T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N.C. & Anderson, K.C. (2006) Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 108, 3441-3449.
11. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. & Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87, 1104-1112.
12. Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M.A. & Anderson, K.C. (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 111, 1654-1664.
13. Chauhan, D., Singh, A.V., Ciccarelli, B., Richardson, P.G., Palladino, M.A. & Anderson, K.C. (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood, 115, 834-845.
14. Chen, D., Pacal, M., Wenzel, P., Knoepfler, P.S., Leone, G. & Bremner, R. (2009) Division and apoptosis of E2f-deficient retinal progenitors. Nature, 462, 925-929.
15. Chua, K.F., Mostoslavsky, R., Lombard, D.B., Pang, W.W., Saito, S., Franco, S., Kaushal, D., Cheng, H.L., Fischer, M.R., Stokes, N., Murphy, M.M., Appella, E. & Alt, F.W. (2005) Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metabolism, 2, 67-76.
16. Dai, Y., Chen, S., Kramer, L.B., Funk, V.L., Dent, P. & Grant, S. (2008) Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical Cancer Research, 14, 549-558.
17. Dai, H., Kustigian, L., Carney, D., Case, A., Considine, T., Hubbard, B.P., Perni, R.B., Riera, T.V., Szczepankiewicz, B., Vlasuk, G.P. & Stein, R.L. (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. The Journal of Biological Chemistry, 285, 32695-32703.
18. Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R., Friedberg, J., Dent, P. & Grant, S. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood, 115, 4478-4487.
19. Davies, F.E., Dring, A.M., Li, C., Rawstron, A.C., Shammas, M.A., O'Connor, S.M., Fenton, J.A., Hideshima, T., Chauhan, D., Tai, I.T., Robinson, E., Auclair, D., Rees, K., Gonzalez, D., Ashcroft, A.J., Dasgupta, R., Mitsiades, C., Mitsiades, N., Chen, L.B., Wong, W.H., Munshi, N.C., Morgan, G.J. & Anderson, K.C. (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood, 102, 4504-4511.
20. Firestein, R., Blander, G., Michan, S., Oberdoerffer, P., Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S., de Cabo, R., Fuchs, C., Hahn, W.C., Guarente, L.P. & Sinclair, D.A. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE, 3, e2020.
21. Ford, J., Jiang, M. & Milner, J. (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Research, 65, 10457-10463.
22. Fu, M., Liu, M., Sauve, A.A., Jiao, X., Zhang, X., Wu, X., Powell, M.J., Yang, T., Gu, W., Avantaggiati, M.L., Pattabiraman, N., Pestell, T.G., Wang, F., Quong, A.A., Wang, C. & Pestell, R.G. (2006) Hormonal control of androgen receptor function through SIRT1. Molecular and Cellular Biology, 26, 8122-8135.
23. Funk, J.A., Odejinmi, S. & Schnellmann, R.G. (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. Journal of Pharmacology and Experimental Therapeutics, 333, 593-601.
24. Grant, S., Easley, C. & Kirkpatrick, P. (2007) Vorinostat. Nature Reviews. Drug Discovery, 6, 21-22.
25. Greenstein, S., Krett, N.L., Kurosawa, Y., Ma, C., Chauhan, D., Hideshima, T., Anderson, K.C. & Rosen, S.T. (2003) Characterization of the MM.1 human multiple myeloma (MM) cell lines. A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Experimental Hematology, 31, 271-282.
26. Haigis, M.C. & Sinclair, D.A. (2010) Mammalian sirtuins: biological insights and disease relevance. Annual Review of Pathology, 5, 253-295.
27. Harper, C.E., Patel, B.B., Wang, J., Arabshahi, A., Eltoum, I.A. & Lamartiniere, C.A. (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-1953.
28. Heltweg, B., Gatbonton, T., Schuler, A.D., Posakony, J., Li, H., Goehle, S., Kollipara, R., Depinho, R.A., Gu, Y., Simon, J.A. & Bedalov, A. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research, 66, 4368-4377.
29. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
30. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J. & Anderson, K.C. (2002) NF-kappa B as a therapeutic target in multiple myeloma. The Journal of Biological Chemistry, 277, 16639-16647.
31. Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. & Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 120, 8567-8572.
32. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7, 585-598.
33. Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 403, 795-800.
34. Jackson, M.D. & Denu, J.M. (2002) Structural identification of 2′- and 3′-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. The Journal of Biological Chemistry, 277, 18535-18544.
35. Kabra, N., Li, Z., Chen, L., Li, B., Zhang, X., Wang, C., Yeatman, T., Coppola, D. & Chen, J. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. The Journal of Biological Chemistry, 284, 18210-18217.
36. Kamel, C., Abrol, M., Jardine, K., He, X. & McBurney, M.W. (2006) SirT1 fails to affect p53-mediated biological functions. Aging Cell, 5, 81-88.
37. Kumar, S., Witzig, T.E., Timm, M., Haug, J., Wellik, L., Fonseca, R., Greipp, P.R. & Rajkumar, S.V. (2003) Expression of VEGF and its receptors by myeloma cells. Leukemia, 17, 2025-2031.
38. Lazebnik, Y.A., Kaufmann, S.H., Desnoyers, S., Poirier, G.G. & Earnshaw, W.C. (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature, 371, 346-347.
39. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 4996-5000.
40. Miller, L.K. (1999) An exegesis of IAPs: salvation and surprises from BIR motifs. Trends in Cell Biology, 9, 323-328.
41. Milne, J.C. & Denu, J.M. (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Current Opinion in Chemical Biology, 12, 11-17.
42. Narala, S.R., Allsopp, R.C., Wells, T.B., Zhang, G., Prasad, P., Coussens, M.J., Rossi, D.J., Weissman, I.L. & Vaziri, H. (2008) SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Molecular Biology of the Cell, 19, 1210-1219.
43. Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kozaki, K., Akishita, M., Ouchi, Y. & Kaneki, M. (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene, 25, 176-185.
44. Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., Qiu, X., Stockman, B., Thanabal, V., Varghese, A., Ward, J., Withka, J. & Ahn, K. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. The Journal of Biological Chemistry, 285, 8340-8351.
45. Podar, K., Tai, Y.T., Davies, F.E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B.K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P. & Anderson, K.C. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98, 428-435.
46. Podar, K., Tai, Y.T., Lin, B.K., Narsimhan, R.P., Sattler, M., Kijima, T., Salgia, R., Gupta, D., Chauhan, D. & Anderson, K.C. (2002) Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with beta 1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCalpha Activation. The Journal of Biological Chemistry, 277, 7875-7881.
47. Rajkumar, S.V. & Witzig, T.E. (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews, 26, 351-362.
48. Sauve, A.A. (2009) Pharmaceutical strategies for activating sirtuins. Current Pharmaceutical Design, 15, 45-56.
49. Sexton, E., Van Themsche, C., LeBlanc, K., Parent, S., Lemoine, P. & Asselin, E. (2006) Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Molecular Cancer, 5, 45.
50. Solomon, J.M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P.S. & Huber, L.J. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Molecular and Cellular Biology, 26, 28-38.
51. Strasser, A., O'Connor, L. & Dixit, V.M. (2000) Apoptosis signaling. Annual Review of Biochemistry, 69, 217-245.
52. Stunkel, W., Peh, B.K., Tan, Y.C., Nayagam, V.M., Wang, X., Salto-Tellez, M., Ni, B., Entzeroth, M. & Wood, J. (2007) Function of the SIRT1 protein deacetylase in cancer. Biotechnology Journal, 2, 1360-1368.
53. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. & Dammacco, F. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073.
54. Wang, R.H., Sengupta, K., Li, C., Kim, H.S., Cao, L., Xiao, C., Kim, S., Xu, X., Zheng, Y., Chilton, B., Jia, R., Zheng, Z.M., Appella, E., Wang, X.W., Ried, T. & Deng, C.X. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 14, 312-323.
55. Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A. & Mayo, M.W. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal, 23, 2369-2380.
56. Yoshizaki, T., Milne, J.C., Imamura, T., Schenk, S., Sonoda, N., Babendure, J.L., Lu, J.C., Smith, J.J., Jirousek, M.R. & Olefsky, J.M. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Molecular and Cellular Biology, 29, 1363-1374.
57. Yuan, Z. & Seto, E. (2007) A functional link between SIRT1 deacetylase and NBS1 in DNA damage response. Cell Cycle, 6, 2869-2871.